meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
<span style="margin-left: 0em;">gene alteration target therapy</span>
<span style="margin-left: 1em;">EGFR gene alteration</span>
<span style="margin-left: 2em;">osimertinib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">durvalumab based treatment</span>
<span style="margin-left: 3em;">durvalumab alone</span>
<span style="margin-left: 4em;">durvalumab plus osimertinib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DCR (1)
DOR (1)
AE (any grade) (1)
TRAE (any grade) (1)
SAE (any grade) (1)
TRAE (grade 3-4) (1)
AE (grade 3-4) (1)
AE leading to death (grade 5) (1)
STRAE (any grade) (1)
Diarrhoea AE (grade 3-4) (1)
Rash AE (grade 3-4) (1)
Pruritus AE (grade 3-4) (1)
Nausea AE (grade 3-4) (1)
Constipation AE (grade 3-4) (1)
Dyspnoea AE (grade 3-4) (1)
Cough AE (grade 3-4) (1)
Back pain AE (grade 3-4) (1)
Arthralgia AE (grade 3-4) (1)
Stomatitis AE (grade 3-4) (1)
Neutropenia AE (grade 3-4) (1)
Dry skin AE (grade 3-4) (1)
Pneumonia AE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
CAURAL (EXPLORATORY), 2019
osimertinib
durvalumab plus osimertinib
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
osimertinib
durvalumab plus osimertinib
osimertinib
---
NA
durvalumab plus osimertinib
NA
---
pathologies: 204 - treatments: 1073
result logic
×
Study list
